Samuel C Markson
Overview
Explore the profile of Samuel C Markson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
85
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Milling L, Markson S, Tjokrosurjo Q, Derosia N, Streeter I, Hickok G, et al.
J Exp Med
. 2024 Feb;
221(4).
PMID: 38411617
In vivo T cell screens are a powerful tool for elucidating complex mechanisms of immunity, yet there is a lack of consensus on the screen design parameters required for robust...
2.
de Sauvage M, Torrini C, Nieblas-Bedolla E, Summers E, Sullivan E, Zhang B, et al.
Neuro Oncol
. 2023 Dec;
26(5):889-901.
PMID: 38134951
Background: Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment; however, only a subset of patients with brain metastasis (BM) respond to ICI. Activating mutations in the mitogen-activated protein kinase signaling...
3.
LaFleur M, Lemmen A, Streeter I, Nguyen T, Milling L, Derosia N, et al.
Nat Immunol
. 2023 Nov;
25(1):178-188.
PMID: 38012416
Annotation of immunologic gene function in vivo typically requires the generation of knockout mice, which is time consuming and low throughput. We previously developed CHimeric IMmune Editing (CHIME), a CRISPR-Cas9...
4.
Collier J, Pauken K, Lee C, Patterson D, Markson S, Conway T, et al.
J Exp Med
. 2023 Jul;
220(10).
PMID: 37432393
Immune-related adverse events (irAEs) are a notable complication of PD-1 cancer immunotherapy. A better understanding of how these iatrogenic diseases compare with naturally arising autoimmune diseases is needed for treatment...
5.
Burke K, Markson S, Sharpe A
Trends Immunol
. 2023 Apr;
44(5):326-328.
PMID: 37031062
In a recent article, Puig-Saus et al. computationally predict and experimentally validate neoantigen-specific T cell responses in patients with melanoma. They identify a restricted set of neoantigens recognized by polyclonal...
6.
Alvarez-Breckenridge C, Markson S, Stocking J, Nayyar N, Lastrapes M, Strickland M, et al.
Cancer Immunol Res
. 2022 Jun;
10(8):996-1012.
PMID: 35706413
Melanoma-derived brain metastases (MBM) represent an unmet clinical need because central nervous system progression is frequently an end stage of the disease. Immune checkpoint inhibitors (ICI) provide a clinical opportunity...
7.
Prakadan S, Alvarez-Breckenridge C, Markson S, Kim A, Klein R, Nayyar N, et al.
Nat Commun
. 2021 Nov;
12(1):7007.
PMID: 34824235
No abstract available.
8.
Prakadan S, Alvarez-Breckenridge C, Markson S, Kim A, Klein R, Nayyar N, et al.
Nat Commun
. 2021 Oct;
12(1):5955.
PMID: 34642316
Leptomeningeal disease (LMD) is a devastating complication of solid tumor malignancies, with dire prognosis and no effective systemic treatment options. Over the past decade, the incidence of LMD has steadily...
9.
White M, Klein R, Shaw B, Kim A, Subramanian M, Mora J, et al.
JAMA Netw Open
. 2021 Aug;
4(8):e2120040.
PMID: 34369989
Importance: Leptomeningeal disease (LMD) is a devastating complication of cancer that is frequently underdiagnosed owing to the low sensitivity of cerebrospinal fluid (CSF) cytologic assessment, the current benchmark diagnostic method....